Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03260322 |
| Title | A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Astellas Pharma Global Development, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | ITA | GBR | ESP | CAN |